USP <797>

USP General Chapter <797> compendially defines the minimum standards for preparing compounded sterile preparations in healthcare and patient‑care environments. It governs conditions and practices that minimize microbial contamination, excessive endotoxin, and visible particulate matter that could harm patients. The chapter applies to pharmacies, hospitals, clinics, and other facilities that compound sterile preparations under Section 503A of the Federal Food, Drug, and Cosmetic Act and analogous state authorities.

Its scope extends from facility design and air classification to garbing, hand hygiene, aseptic manipulation, cleaning and disinfection, environmental monitoring, release checks, and beyond‑use dating. It also mandates personnel qualifications proven through gloved‑fingertip sampling and an aseptic process simulation using growth media. These elements must be described in procedures, executed as written, and verified with documented evidence.

USP 797 does not replace current good manufacturing practice for outsourcing facilities or manufacturers. 503B outsourcing facilities compound under FDA‑enforced CGMP and, while they may consider USP 797 principles for clinical risk control, compliance is anchored in 21 CFR Parts 210 and 211 and related guidance. In ambulatory and acute‑care settings, however, USP 797 is the primary sterile compounding benchmark referenced by state boards of pharmacy and quality accrediting bodies.

Compounded sterile preparations span ready‑to‑use doses, batch‑prepared small volumes, and more complex manipulations such as reconstitution, pooling, and transfers. USP 797’s risk‑based “category” structure matches beyond‑use dating and control intensity to the compounding environment and process complexity. Programs must align training, facilities, and monitoring accordingly, then reassess on a defined cadence.

USP–NF standards are recognized under the Federal Food, Drug, and Cosmetic Act. USP 797 is not an FDA regulation, but it is widely incorporated by reference in state pharmacy laws and accreditation criteria. FDA oversight focuses on patient safety and product quality; adverse events, insanitary conditions, or interstate commerce issues can trigger federal action regardless of state adoption status.

Technically, USP 797 aligns with cleanroom and microbial control principles familiar from sterile manufacturing. It references air cleanliness by particle counts and relies on pressure differentials, HEPA‑filtered unidirectional airflow at the point of exposure, and hygienic gowning practices to maintain an aseptic compounding zone. The chapter expects routine surface and air sampling, trend analysis, and corrective action when excursions occur.

Neighboring USP chapters complete the toolkit. USP 800 governs hazardous drug handling, integrating with 797 when compounding sterile antineoplastics. USP 788 sets particulate matter limits for injections, relevant when selecting components and establishing visual inspection steps. Media‑fill testing is supported by established aseptic process simulation practices. These connections ensure that sterility assurance is not reduced to a single control, but delivered through layered barriers.

Internationally, the principles resonate with ISO cleanroom standards and the expectations reflected in EU GMP Annex 1 for sterile products. While healthcare compounding and commercial manufacturing operate under different legal frameworks, both rely on validated facility controls, trained personnel, and documented environmental performance to reduce contamination risk to an acceptable level.

Facilities should maintain a governance map that traces which elements of USP 797 are adopted by state law, accreditation, or internal policy, and where other authorities apply. This avoids gaps when inspections occur and frames how changes to USP 797 translate into local procedures and competencies.

USP 797 requires that the critical site of exposure to the sterile product be protected within a primary engineering control that delivers unidirectional HEPA‑filtered air at a cleanliness level consistent with aseptic manipulation. The primary device is typically located in a buffer room supplied with clean, conditioned air and segregated from less controlled spaces by an anteroom. Pressure differentials and appropriate air change rates maintain directional flow from clean to less clean areas.

For lower‑risk operations with short beyond‑use dates, a segregated compounding area may be acceptable, but this does not replace the need for a properly certified primary engineering control. Facilities must document room pressurization, airflow patterns, and classification, then recertify at defined intervals or after significant changes. Certification includes particle counts, smoke studies at the work zone, and verification of HEPA integrity.

Work practices sustain the protection that the air system provides. Operators should stage materials to minimize turbulence, disinfect vial stoppers and surfaces with appropriate contact times, and avoid blocking first air. Consumables, wipes, and disinfectants must be compatible with the environment and validated for their intended microbial spectrum, including periodic sporicidal application.

Monitoring confirms that the engineered state is real. USP 797 expects both nonviable particle data and viable sampling to assess performance. Trending by location and shift can reveal deterioration early, allowing targeted remediation before patient risk emerges.

• Define room classifications, pressure relationships, and air change rates in a current plan that reflects as‑built conditions and certification data.
• Locate the primary engineering control to protect critical sites, with documented smoke studies showing unidirectional flow in the work zone.
• Maintain a cleanable, durable envelope and a sanitation and cleaning schedule that covers daily and periodic tasks, including sporicide.
• Trend nonviable counts, viable air and surface data, and certification results to detect drift and trigger investigation.

Human operators are the dominant contamination source during aseptic compounding. USP 797 requires systematic hand hygiene and garbing before entering controlled spaces and prescribes the sequence in which each item is donned and disinfected. Facilities must provide sinks and supplies positioned to avoid recontamination, and they must maintain clear, illustrated instructions that match the physical layout.

Competency is demonstrated, not declared. Before compounding independently, each person must pass gloved‑fingertip sampling to show proper aseptic technique and hand hygiene, and must complete an aseptic process simulation using growth media to mimic representative manipulations. These assessments are repeated at defined intervals, with increased frequency after failures, extended absences, or process changes.

Observation by qualified evaluators complements microbiological checks. Technique assessments confirm that operators maintain first air, disinfect vial septa correctly, and avoid practices that shed particulates or disturb airflow. Retraining follows a documented plan, and failure thresholds and requalification steps are spelled out to avoid ad hoc decisions during an event.

Programs should capture evidence of learning and ongoing proficiency. Written tests, practice checklists, and microbiological results are archived in a retrievable format, enabling the quality unit to show inspectors that each person was qualified before performing specific tasks and has remained qualified through periodic reassessments.

Anchoring competency with objective measures

• Use glove‑print monitoring with defined acceptance criteria for initial and ongoing qualifications.
• Execute a media‑fill aseptic process simulation that mirrors worst‑case manipulations, components, and durations.
• Document observation‑based technique assessments and link them to retraining and requalification steps.
• Tie qualification status to access controls so only qualified personnel can compound or verify.

Cleaning and disinfection sustain the controlled state established by engineering. USP 797 expects a hierarchically defined program that specifies the agents used, concentrations, contact times, and frequencies for each surface and room type. Daily tasks, such as work surface disinfection, sit alongside periodic activities like sporicidal application and ceiling or wall cleaning. Agents are selected for material compatibility and verified for spectrum against likely flora.

Environmental monitoring verifies that microbial and particulate levels remain within limits appropriate for the space and operations. Programs include nonviable particle counting, active air sampling, surface contact plates or swabs, and fingertip sampling linked to garbing assessments. Locations are risk‑based, capturing critical sites, traffic pathways, and difficult‑to‑clean zones. Frequencies support trending that is granular enough to detect drift and seasonal variation.

Results are not just pass or fail. They feed a trend analysis that distinguishes random variation from meaningful shifts, including persistent recovery of the same organism or slow increases around high‑risk activities. Investigations follow a structured approach and may involve intensified cleaning, maintenance, retraining, or procedural changes, with effectiveness checks documented to closure.

Sampling and analysis methods must be controlled. Media lot traceability, transport conditions, incubation regimes, and identification methods are defined and qualified. Deviations, such as delayed incubation or equipment malfunction, are captured and assessed for potential impact on patient safety and data integrity.

Program integration

Tie sampling locations and frequencies to a written environmental monitoring program that meshes with your sanitation and cleaning schedule and bioburden monitoring. Use environmental monitoring (EM) data to drive preventive actions rather than waiting for excursions.

USP 797 links beyond‑use dates to the robustness of controls and the conditions under which a compounded sterile preparation is made and stored. The category structure reflects environment, process complexity, and testing. Preparations made in a segregated compounding area are assigned short beyond‑use dates, while operations in a classified cleanroom suite with enhanced controls, and when applicable, supporting sterility and stability data, can justify longer dating.

Release decisions must consider labeling accuracy, component verification, visual inspection for particulates and container integrity, and any required testing. Temperature control from compounding through storage and distribution protects product quality. Deviations, such as brief temperature excursions, are evaluated with a documented rationale that aligns with stability knowledge and risk to patients.

Process checks during compounding reduce downstream risk. Independent verification of calculations and volumes, line clearances in the work area, and reconciliation of critical components prevent mix‑ups. Documentation captures who did what, when, and how it was checked, creating a clear history for each lot or dose.

Assign beyond‑use dates conservatively and document the basis, including environmental conditions, manipulations performed, and any applicable testing or literature. Apply in‑process controls and in‑process verification to prevent defects at the source, and ensure temperature monitoring protects quality through storage and use.

Materials and water used to dilute or transfer products must meet their compendial or manufacturer specifications. For purified water systems and quality verification, consult the expectations summarized in the purified water supplement.

USP 797 presumes a functioning quality system that ensures consistency of practice, captures evidence of control, and supports continuous improvement. Policies and procedures define how activities are performed and by whom. Records demonstrate that procedures were followed, exceptions were evaluated, and corrective actions were effective. The quality unit maintains independence sufficient to make product disposition and programmatic decisions.

Documentation must be contemporaneous, attributable, legible, original, and accurate. Electronic systems that hold training, environmental, or batch records should meet requirements for security, audit trails, and reliable retrieval. Periodic review confirms that forms and instructions remain fit for purpose as facilities, components, and techniques evolve.

Deviations and complaints are signals. A structured pathway classifies issues, assigns investigation depth, documents root causes, and verifies effectiveness of actions. Trends in recurring minor deviations can be as insightful as single major events if they expose a systemic weakness. Management reviews synthesize these inputs, allocate resources, and track commitments to closure.

Training, qualification, and change control knit the system together. Personnel must be qualified before performing tasks, and planned changes to equipment, layout, or disinfectants are assessed for risk to aseptic performance, then implemented with documented verification or requalification as indicated.

• Maintain controlled SOPs with periodic document review and real‑time document control.
• Use structured deviations and audit readiness workflows to capture, investigate, and close issues.
• Adopt compliant recordkeeping with 21 CFR Part 11 features, including audit trails and access control.
• Apply review by exception to highlight critical data and trends in environmental and batch records.

Many citations stem from strong written procedures that are weak in execution. Operators drift from the validated garbing sequence, disinfectants are rotated without attention to contact times, and staging practices slowly encroach on airflow that once was verified by smoke studies. Routine observation and retraining curb these behaviors before they become normalized deviations.

Another frequent gap lies in environmental data that are collected but not analyzed. Recoveries repeat at the same sites or during the same shifts, yet no one correlates results with cleaning, maintenance, or workload. Effective programs treat trend review as a standing activity, elevate weak signals, and intervene when patterns emerge, even if action levels are not breached.

Beyond‑use dates can be overstated when assumptions about storage or workflow do not match reality. Temperature excursions, transport delays, or component substitutions undermine the basis for dating if not accounted for. A conservative approach, backed by documented rationale and surveillance of real‑world conditions, reduces patient risk and inspection findings.

Lastly, competency checks sometimes become calendar exercises. If the media‑fill scenario does not reflect worst‑case manipulations, or gloved‑fingertip sampling follows an unrepresentative workflow, false reassurance results. Design assessments to stress technique, then respond proportionally to any failures with retraining and requalification.

• Re‑perform smoke studies after layout changes and re‑teach staging to protect first air.
• Correlate environmental monitoring data with cleaning, maintenance, and staffing to find root causes.
• Base dating on the assigned temperature monitoring profile and documented handling practice.
• Align media‑fill scenarios with worst‑case manipulations and durations.

USP 797 intersects with several specialized frameworks. When compounding hazardous sterile drugs, USP 800 requirements for containment, negative pressure rooms, and personnel protection apply in addition to 797’s aseptic controls. Programs must reconcile any tension between containment and first‑air protection with careful layout, pressure monitoring, and work practices that minimize risk in both dimensions.

Particulate control anchors visual inspection and component selection. USP 788 sets limits on particulate matter in injections, reinforcing the need for clean components, proper filtration when indicated, and vigilant inspection practices to prevent avoidable particles from reaching patients. It complements microbiological controls by focusing on a distinct harm mechanism.

Although healthcare compounding differs from commercial manufacturing, EU GMP Annex 1 illustrates the depth of control expected for sterile products in regulated industry. Its emphasis on contamination control strategy, closed systems, and cleanroom discipline provides useful perspective for compounding programs seeking to strengthen their defenses without overbuilding.

Radiopharmaceutical compounding incorporates radiation safety and decay‑driven timelines alongside aseptic expectations. Dedicated guidance clarifies how aseptic technique, facility controls, and verification steps are adapted to radioactive materials and time‑critical use. Cross‑functional governance is essential so that radiation and sterility assurance objectives are met simultaneously.

Boundary definitions help teams decide when to escalate from healthcare compounding expectations to manufacturing‑style controls. Complex manipulations, longer storage horizons, or distribution beyond the immediate patient population should trigger heightened scrutiny of facility classification, validation practices, and oversight.

• Coordinate USP 797 with USP 800 for hazardous sterile compounding.
• Consider USP 788 when designing inspection and filtration steps.
• Benchmark cleanroom discipline against EU GMP Annex 1 where appropriate.
• Use the radiopharma readiness guide to align aseptic and radiation safety workflows: USP 825 radiopharma.
• Clarify your sterile aseptic supplement boundary when processes approach manufacturing complexity.

A pragmatic implementation begins with a gap assessment against the currently official USP 797 text and any state‑specific adoptions. Map facilities, workflows, and competencies to chapter expectations, then prioritize remediation by patient risk. Early wins often come from clarifying garbing sequences, formalizing disinfection contact times, and tightening documentation of certification and pressure monitoring.

Next, stabilize the environmental monitoring program. Define locations, frequencies, and action levels, then establish trend reviews that feed management decisions. Ensure your cleaning agents, sporicide cadence, and residue removal steps are realistic for the materials in use and are verifiable during inspections.

Codify personnel qualification. Build media‑fill scenarios that reflect worst‑case manipulations and durations, and connect qualification status to access privileges in the cleanroom. Define triggers for requalification and codify how to handle failures without improvisation.

Finally, strengthen process controls and beyond‑use dating. Verify calculations and volumes with independent checks, stage components to protect first air, and establish conservative dating with documented rationale. Align labeling, storage, and temperature monitoring with your dating strategy and verification plans.

• Start with a structured readiness effort: USP 797 sterile compounding readiness.
• Calibrate workflows and checks against in‑process controls and in‑process verification.
• Reinforce material control during weigh and dispense and staging.
• Embed routine review of environmental monitoring trends into management meetings.

V5 Ultimate operationalizes USP 797 requirements through integrated procedures, role‑based execution, and defensible records. Electronic forms guide hand hygiene, garbing, and staging steps in sequence, while controlled checklists collect certification data, pressure readings, and cleaning events with time‑stamped attribution. Supervisors see at a glance which personnel are qualified to compound or verify based on current assessments.

Environmental data flow from scheduled sampling loads to exception‑driven review queues. Trending identifies recurring organisms, seasonal shifts, and hotspot locations, and corrective actions are routed with deadlines and effectiveness checks. Batch and dose records incorporate independent verifications and reconcile critical components, creating a clear lineage from calculation to label to release.

Hardware integrations minimize transcription risk. Scales, sensors, and primary engineering control logs feed directly into the record. Temperature devices support continuous storage monitoring and excursion assessment. Media‑fill and gloved‑fingertip results are tied to each person’s profile, driving access controls in the cleanroom and alerting when requalification is due.

Quality oversight is baked in. Deviations, complaints, and audit observations follow structured workflows with root cause, CAPA, and management review. Document control keeps procedures current and retrievable, while audit trails demonstrate who changed what and when. The result is a program that is not only compliant on paper, but also demonstrably in control during inspections.